Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.78 |
| ▸ | HTR1D | P28221 | 7/20 | 0.66 |
| ▸ | HTR1B | P28222 | 7/20 | 0.66 |
| ▸ | HTR1A | P08908 | 6/20 | 0.66 |
| ▸ | HTR2A | P28223 | 3/20 | 0.66 |
| ▸ | HTR7 | P34969 | 3/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949519 | 0.88 | HTR6 (1.00) | HTR6HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL3952668 | 0.85 | HTR6 (0.63) | HTR6HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL8109947 | 0.77 | MAPT (0.63) | HTR6HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL6970866 | 0.76 | HTR6 (1.00) | HTR6HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL17740376 | 0.76 | HTR6 (0.65) | HTR6HTR1AHTR2AHTR7DRD3 | |
| SCHEMBL7465991 | 0.74 | HTR6 (0.88) | HTR6HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL8117310 | 0.74 | MALT1 (0.57) | HTR6HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL3947189 | 0.73 | HTR6 (1.00) | HTR6HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL2055424 | 0.73 | CYP3A4 (0.59) | HTR6KMT2A | |
| SCHEMBL3947299 | 0.73 | HTR6 (1.00) | HTR6HTR1DHTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450806-B1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB PUBL (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1450806-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166663-A1 | Use | BIOVITRUM AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003039547-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166663-A1 | Use | SULT2A1, SULT1A1, SLC5A1 | HTR6 1402/4885HTR1D 971/4885HTR1B 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.